Cellectis SA is a gene-editing company. The company focused on developing immunotherapies based on gene edited engineered CAR-T cells. Cellectis SA is based in Paris, France.
| Revenue (Most Recent Fiscal Year) | $79.59M |
| Net Income (Most Recent Fiscal Year) | $-67.59M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | 5.57 |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 5.84 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -85.46% |
| Net Margin (Trailing 12 Months) | -84.92% |
| Return on Equity (Trailing 12 Months) | -69.38% |
| Return on Assets (Trailing 12 Months) | -19.51% |
| Current Ratio (Most Recent Fiscal Quarter) | 1.62 |
| Quick Ratio (Most Recent Fiscal Quarter) | 1.62 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.98 |
| Inventory Turnover (Trailing 12 Months) | -- |
| Book Value per Share (Most Recent Fiscal Quarter) | $0.76 |
| Earnings per Share (Most Recent Fiscal Quarter) | -- |
| Earnings per Share (Most Recent Fiscal Year) | -- |
| Diluted Earnings per Share (Trailing 12 Months) | $-0.67 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 100.34M |
| Free Float | 83.87M |
| Market Capitalization | $443.50M |
| Average Volume (Last 20 Days) | 0.04M |
| Beta (Past 60 Months) | 2.91 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 16.41% |
| Percentage Held By Institutions (Latest 13F Reports) | 63.90% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |